|
Synonyms: LY-3819253 | LY-CoV555 | LY3819253
Compound class:
Antibody
Comment: Bamlanivimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2. It was developed by Eli Lilly, but such is the speed of COVID-19 therapeutic development, there are no peer-reviewed articles that report its design, preclinical or early clinical data.
|
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 11876 | bamlanivimab |
| Synonyms |
| LY-3819253 | LY-CoV555 | LY3819253 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 1104 |
| Other databases | |
| GtoPdb PubChem SID | 434321760 |
| Search PubMed clinical trials | bamlanivimab |
| Search PubMed titles | bamlanivimab |
| Search PubMed titles/abstracts | bamlanivimab |
